Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) (NCT07048886)

🧪 Interventions in This Study

• Rocklatan (netarsudil 0.02% and latanoprost 0.005%) (DRUG)
• Systane (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Center for Sight — Las Vegas, Nevada

📞 Contact the Study Coordinator

Phone: (702) 724-2005

Email: jodi.kennedy@c4slv.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Primary Open Angle Glaucoma

• A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) — Panama City,
• Advanced Glaucoma Progression Study — Los Angeles, California
• Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study — Palo Alto, California
• A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma — Glendale, Arizona
• Hydrus® Microstent New Enrollment Post-Approval Study — Irvine, California

Explore by condition: All Primary Open Angle Glaucoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.